Patients with cystic fibrosis to have access to Kaftrio (ivacaftor/tezacaftor/elexacaftor) under deal between NHS and Vertex

The deal, which will last for four years, was negotiated ahead of a licence being granted by the European Medicines Agency, and means that clinicians will be free to start prescribing the triple treatment to English patients as soon as the licence is granted, in the coming weeks.

SPS commentary:

As part of the agreement with NHS England, Vertex has committed to submit Orkambi (ivacaftor and lumacaftor) Symkevi (tezacaftor and ivacaftor) and Kaftrio to NICE for a technology appraisal, within an agreed upon timetable, allowing for a period of real-world data collection on the medicines.


NHS England

Resource links:

BioSpace report